Codexis (CDXS) Projected to Post Earnings on Thursday

Codexis (NASDAQ:CDXS) is expected to be issuing its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect the company to post earnings of ($0.0957) per share and revenue of $18.72 million for the quarter. Individuals can find conference call details on the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.

Codexis (NASDAQ:CDXS) last posted its earnings results on Tuesday, August 11th. The biotechnology company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.01. Codexis had a negative net margin of 39.55% and a negative return on equity of 74.36%. The firm had revenue of $14.91 million for the quarter, compared to analyst estimates of $13.82 million. On average, analysts expect Codexis to post ($0.37) EPS for the current fiscal year and ($0.25) EPS for the next fiscal year.

Codexis Stock Performance

Shares of Codexis stock opened at $1.26 on Thursday. The company’s fifty day moving average is $1.42 and its 200 day moving average is $1.81. Codexis has a twelve month low of $0.96 and a twelve month high of $2.98. The stock has a market cap of $137.98 million, a price-to-earnings ratio of -3.71 and a beta of 2.55. The company has a quick ratio of 2.99, a current ratio of 3.06 and a debt-to-equity ratio of 1.03.

Analyst Ratings Changes

Several analysts recently commented on CDXS shares. Benchmark reiterated a “hold” rating on shares of Codexis in a report on Thursday, August 20th. Weiss Ratings raised Codexis from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, October 23rd. Wall Street Zen downgraded Codexis from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. Finally, Piper Sandler dropped their price target on Codexis from $9.00 to $8.00 and set an “overweight” rating on the stock in a research note on Monday, August 17th. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Codexis has a consensus rating of “Hold” and an average target price of $6.50.

Codexis Company Profile

Codexis, Inc is a biotechnology company that develops enzymes and other biocatalytic technologies for use in pharmaceutical and biomanufacturing applications. Its proprietary CodeEvolver protein-engineering platform is designed to improve the performance of naturally occurring enzymes, including their activity, selectivity, stability and production characteristics.

The company works with pharmaceutical and biotechnology companies to develop biocatalysts used in the manufacture of active pharmaceutical ingredients, intermediates and other complex molecules.